Frontlight ResearchEarly access
Duchenne muscular dystrophy trials in France
13 of 17 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
- Where
- Nantes, Paris
- Age
- 7 years to 16 years
- People
- 70 worldwide
- Run by
- Avidity Biosciences, Inc.
See details and how to joinNCT07587242 - Phase 3Taking peopleStudy in which all the patients take the same investigational drug with the aim of evaluate the long-term safety, tolerability, and efficacy of GIVINOSTAT in all the patients affected with Duchenne Muscolar Dystrophy who have been already treated in one of the GIVINOSTAT studies in the past
- Where
- Lille Cedex, Marseille, Nantes, Paris
- Age
- Up to 64 years
- People
- 207 worldwide
- Run by
- Italfarmaco S.p.A.
See details and how to join2023-504520-26-00 - No phaseTaking peopleTranscriptomic Analysis to Put an End to Misdiagnosis in Patients With Rare Muscle Diseases
- Where
- Marseille
- People
- 50
- Run by
- Assistance Publique Hopitaux De Marseille
See details and how to joinNCT06833489 - Phase 2/3Taking peopleA Clinical Study to Assess Safety, Efficacy and Pharmacodynamic Profile of GNT0004 in Duchenne Muscular Dystrophy
- Where
- Bordeaux Cedex, Brest Cedex 2, Bron, Lille Cedex, Montpellier, Paris, Strasbourg Cedex 2
- Age
- 6 years to 10 years
- People
- 77 worldwide
- Run by
- Genethon
See details and how to joinNCT07856329 · EU 2023-505187-11-00 - Phase 3Not yet taking people in FranceA Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
- Where
- Paris, Strasbourg Cedex 2
- Age
- 7 years to 11 years
- People
- 80 worldwide
- Run by
- Solid Biosciences Inc.
See details and how to joinNCT07160634 · EU 2025-522949-22-00 - Phase 2Enrolling by invitationOpen-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
- Where
- Marseille, Nantes, Nice, Paris
- People
- 260 worldwide
- Run by
- Edgewise Therapeutics, Inc.
See details and how to joinNCT06066580 - Phase 1/2Not yet taking people in FranceA Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44
- Where
- Paris, Toulouse Cedex 9
- Age
- 4 years to 20 years
- People
- 24 worldwide
- Run by
- Entrada Therapeutics, Inc.
See details and how to joinNCT07037862 · EU 2024-517584-23-00 - Phase 1/2Not yet taking people in FranceA Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45
- Where
- Bron, Paris, Toulouse Cedex 9
- Age
- 4 years to 20 years
- People
- 24 worldwide
- Run by
- Entrada Therapeutics, Inc.
See details and how to joinNCT07038824 · EU 2024-517499-39-00 - Phase 3Taking peopleEfficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
- Where
- Lille Cedex, Marseille, Paris
- Age
- 9 years to 17 years
- People
- 138 worldwide
- Run by
- Italfarmaco
See details and how to joinNCT05933057 · EU 2023-503521-19-00 - Phase 3Not yet taking people in FranceA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping
- Where
- Nantes, Paris
- Age
- Up to 17 years
- People
- 42 worldwide
- Run by
- Avidity Biosciences Inc.
See details and how to join2025-523087-20-00 - Phase 1/2Taking peoplePhase 1/2a study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of SQY51 in Paediatric and Adult Patients with a Genetically Confirmed Diagnosis of Duchenne Muscular Dystrophy
- Where
- Garches
- Age
- Up to 64 years
- People
- 12
- Run by
- Sqy Therapeutics
See details and how to join2022-500703-49-01 - No phaseTaking peopleEvaluation of the Role of miR-1 in the Pathogenesis and as a Biomarker in Muscular Dystrophies and Congenital Myopathies
- Where
- Clermont-Ferrand
- Age
- 2 years and over
- People
- 104
- Run by
- University Hospital, Clermont-Ferrand
See details and how to joinNCT07415837 - Phase 2/3Enrolling by invitationGivinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- Where
- Nantes, Paris
- Age
- 7 years and over
- People
- 206 worldwide
- Run by
- Italfarmaco
See details and how to joinNCT03373968